Heart failure
Conditions
Interventions
experimental group:Combined use of Lusemendan based on the control group.
Control group,:On top of basic treatment, treat with recombinant human brain natriuretic peptide
Sponsors
Meizhou People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for heart failure and is a patient with acute chronic heart failure (AHF); 2. Age between 18 and 75 years; 3. New York Heart Association (NYHA) functional classification II-IV; 4. Patient or their family has signed the informed consent form and voluntarily participates in this study; 5. No other severe heart diseases or comorbidities, such as acute myocardial infarction, severe arrhythmias, etc.
Exclusion criteria
Exclusion criteria: 1. Severe liver or kidney dysfunction that may affect drug metabolism and excretion; 2. Allergy to recombinant human brain natriuretic peptide or levosimendan; 3. Recent (within 3 months) cardiac surgery or interventional treatment; 4. Severe neurological or psychiatric disorders affecting the evaluation of treatment efficacy; 5. Participation in other clinical trials that may affect the accuracy of this study's results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| left ventricular ejection fraction, LVEF ;N-terminal Pro-brain Natriuretic Peptide, NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life; | — |
Countries
China
Contacts
Public ContactLi Pu
Meizhou People's Hospital
Outcome results
None listed